Publications by authors named "Jill Maaske"
In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the U.S., Chile, and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured four weeks after two doses were assessed as correlates of risk and protection against PCR-confirmed symptomatic SARS-CoV-2 infection (COVID-19).
View Article and Find Full Text PDFArticle Synopsis
- Breakthrough SARS-CoV-2 infections in vaccinated individuals generally lead to milder disease compared to unvaccinated people, highlighting the benefits of vaccination during the pandemic.
- In a study involving AZD1222 (ChAdOx1 nCoV-19) vaccinees, results showed they experienced lower incidence, shorter duration of symptoms, and reduced viral loads compared to placebo recipients.
- Vaccinated individuals exhibited strong immune responses, including increased antibody production and T-cell responses, which were linked to better control of the virus and reduced transmission potential.
Article Synopsis
- - The nasal mucosa is a key defense point against SARS-CoV-2, but vaccines given through injections typically don't produce strong antibody responses there.
- - In a study of over 3,000 participants, researchers found that after getting the AZD1222 vaccine, detectable levels of IgG antibodies were present in nasal fluid, especially after the second dose, and these were correlated with serum IgG levels.
- - The vaccine led to a strong immune response, with significant enhancements in nasal IgG levels that associated with decreased viral loads and shorter shedding durations during breakthrough infections.
Article Synopsis
- - The study evaluated the safety, efficacy, and immune response of the AZD1222 COVID-19 vaccine in a phase 3 trial with 21,634 participants receiving the vaccine and 10,816 receiving a placebo.
- - Results showed the vaccine had a 67.0% effectiveness at preventing symptomatic COVID-19 in participants with no prior SARS-CoV-2 infection, and maintained lower incidence rates of COVID-19 over 6 months post-vaccination.
- - The AZD1222 vaccine was found to be safe and well tolerated, with effective immune responses observed, although there was a decrease in immunity by Day 180 post-vaccination.
Background: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known.
Methods: In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru.
Results: A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants).
Aim: To report the results of a 104-week extension to a 52-week study in which dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic control, liver fat and metabolic variables compared with glimepiride (GLIM) in participants with type 2 diabetes (T2D) receiving background metformin.
Materials And Methods: This extension to a 52-week global, multicentre, parallel-group, active-controlled, double-blind study (NCT02419612) continued randomized participants (1:1) on DAPA+SAXA (10/5 mg) plus placebo, or GLIM (1-6 mg) plus placebo, once daily. Eligible participants were aged ≥18 years, had T2D (glycated haemoglobin [HbA1c] 58.
Aim: To assess the effects of dapagliflozin plus saxagliptin plus metformin versus glimepiride plus metformin on liver fat (proton density fat fraction) and visceral and subcutaneous adipose tissue volumes over 52 weeks of treatment.
Materials And Methods: This was a magnetic resonance imaging substudy of a 52-week, multicentre, randomized, double-blind, parallel-group trial that evaluated the efficacy and safety of dapagliflozin 10 mg/day plus saxagliptin 5 mg/day versus titrated glimepiride 1-6 mg (1, 2, 3, 4 or 6 mg) in 82 patients with type 2 diabetes (HbA1c 7.5%-10.
Aims: To evaluate the efficacy and safety of dapagliflozin (DAPA) + saxagliptin (SAXA) compared with glimepiride (GLIM) in patients with type 2 diabetes who were inadequately controlled [glycated haemoglobin (HbA1c) 7.5-10.5% (58-91 mmol/mol)] on metformin monotherapy.
View Article and Find Full Text PDFObjective: To analyze the relationship between glycemic control after renal transplantation and subsequent graft function and complications.
Methods: We conducted a retrospective chart review of 202 consecutive patients undergoing kidney transplantation to analyze the association between perioperative and chronic glycemic control and clinical outcomes of rejection, infection, and hospital readmission during the first year after kidney transplantation.
Results: Mean in-hospital blood glucose (BG) was 157 ± 34.